Attached files
Exhibit 10.22
AGREEMENT AND AMENDMENT NO. 2
This AGREEMENT AND AMENDMENT NO. 2 is made this 1st day of April 2015, and effective as of January 1, 2015, by and between ORAMED PHARMACEUTICALS INC., a Delaware corporation with a mailing address at Hi-Tech Park 2/4 Givat Ram, Jerusalem 91390 Israel (the “Company”), and Michael Berelowitz, M.D., with an address 415 East 37th Street New York, NY 10016 (“Berelowitz”).
WHEREAS:
| A. | The Company and Berelowitz are parties to the Agreement dated as of November 26, 2013, as amended on July 16, 2014 (together, the “Original Agreement”); and |
| B. | The Company and Berelowitz wish to amend the Original Agreement to extend the term thereof for an additional twelve months. |
NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, the parties hereto covenant and agree as follows:
| 1. | Amendment to Section 1.2. Section 1.2 of the Original Agreement is hereby amended and restated in its entirety to read as follows: |
| “2.1 | Term. Unless terminated earlier in accordance with the provisions hereof, the term of engagement under this Agreement shall commence on January 1, 2015 (the “Effective Date”) and shall continue for a period of twelve months (the “Term”).” |
| 2. | Ratification. As amended hereby, the Original Agreement is ratified and confirmed and all other terms and conditions remain in full force and effect. |
[Signature page follows.]
| -2- |
IN WITNESS WHEREOF the parties hereto have executed this Agreement and Amendment No. 2 effective as of the date and year first above written.
| ORAMED PHARMACEUTICALS INC. | |||
| Per: | /s/ Nadav Kidron, /s/ Yifat Zommer |
/s/ Michael Berelowitz | |
MICHAEL BERELOWITZ M.D. | |||
| Name: | Nadav Kidron / Yifat Zommer | ||
| Title: | Chief Executive Officer / CFO | ||